Novartis (NVS) says its RNA therapy braxlosiran (del-brax), added from its $12B acquisition of Avidity Biosciences in February, succeeded in a Phase 1/2 trial for facioscapulohumeral muscular ...

June 11 (Reuters) - Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of ...

University of Maine researchers have published new findings about how muscles form, why certain muscle diseases develop and ...

A new treatment platform developed by researchers at the University of Texas MD Anderson Cancer Center was able to deliver ...

University of Maine researchers have published new findings about how muscles form, why certain muscle diseases develop and ...

When it comes to muscular diseases, most of us have heard of especially common ones like muscular dystrophy and Lou Gehrig's disease. But one of the rarest muscular disorders is also one of the most ...

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying ...

France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a ...

Different types of liver disease are leading to distinct signatures of muscle loss, according to a new study that could help ...

Peter Frampton, 76, discusses living with Inclusion Body Myositis, a rare, progressive muscle disease that is changing how he ...

Add Yahoo as a preferred source to see more of our stories on Google. Despite being so rare, "improved awareness and diagnostic techniques have led to more frequent diagnoses and better care," says ...